Sutro raises $26 million in D round

Sutro Biopharma Inc. (South San Francisco, Calif.) raised $26 million in a series D round led by existing investors Alta Partners; Amgen Ventures; Celgene Corp. (NASDAQ:CELG); Lilly Ventures; Skyline Ventures; and SV Life Sciences. Sutro is using its cell-free protein synthesis technology to generate bispecific antibodies and site-specific antibody-drug conjugates (ADCs) with unnatural amino acids. The company's internal pipeline includes undisclosed preclinical ADC programs. Sutro said it plans to advance a bispecific antibody for immunology or cancer indications into the clinic in the next 12-18 months. ...